Study record managers: refer to the Data Element Definitions if submitting registration or results information. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Taxol Weekly Better Than Every Three Weeks for Breast Cancer
Docetaxel in Treating Patients With Metastatic Breast Cancer - Full Text View - satocoinfo.com
A study found that getting Taxol chemical name: paclitaxel weekly had more benefits than getting Taxol every 3 weeks for women diagnosed with breast cancer that had spread to the lymph nodes or women diagnosed with breast cancer that hadn't spread to the lymph nodes but was considered high risk. Getting Taxol every week also had more benefits than getting Taxotere chemical name: docetaxel weekly or every 3 weeks for these women. In this study of 5, women, more women who received Taxol once a week were likely to be alive and free of breast cancer 5 years after being diagnosed compared to women who received Taxol every 3 weeks OR women who received Taxotere either weekly or every 3 weeks. All the women received Adriamycin chemical name: doxorubicin and Cytoxan chemical name: cyclophosphamide before receiving either Taxol or Taxotere. For women diagnosed with early-stage, lymph-node-positive breast cancer, treatment often includes chemotherapy with Adriamycin and Cytoxan followed by a taxane.
Docetaxel in Treating Patients With Metastatic Breast Cancer
Examples: Cancer AND drug name. Pneumonia AND sponsor name. How to search [pdf]. For these items you should use the filters and not add them to your search terms in the text field.
Study record managers: refer to the Data Element Definitions if submitting registration or results information. Patients are stratified according to prior taxane use yes vs no , number of prior chemotherapy regimens for metastatic disease 0 vs 1 , and participating center. Patients are randomized to one of two treatment arms.